Your browser doesn't support javascript.
loading
iTRAQ-based pharmacoproteomics reveals potential targets of berberine, a promising therapy for ulcerative colitis.
Li, Yan-Hong; Sun, Wei; Zhou, Bao-Jin; Rosenstein, Adam; Zhao, Jie; Wang, Jian; Bian, Zhao-Xiang.
Affiliation
  • Li YH; School of Medicine, South China University of Technology, Guangzhou, China; Hong Kong Baptist University Shenzhen Research Institute and Continuing Education, Shenzhen, China. Electronic address: liyh2016@scut.edu.cn.
  • Sun W; State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences Beijing, Beijing Institute of Radiation Medicine, Beijing, China.
  • Zhou BJ; Deepxomics Co., Ltd., Shenzhen, China.
  • Rosenstein A; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Zhao J; School of Medicine, South China University of Technology, Guangzhou, China.
  • Wang J; School of Medicine, South China University of Technology, Guangzhou, China. Electronic address: jwangsc@scut.edu.cn.
  • Bian ZX; Hong Kong Baptist University Shenzhen Research Institute and Continuing Education, Shenzhen, China; Laboratory of Brain and Gut Research, Hong Kong Chinese Medicine Research Center, School of Chinese Medicine, Hong Kong, China. Electronic address: bzxiang@hkbu.edu.hk.
Eur J Pharmacol ; 850: 167-179, 2019 May 05.
Article in En | MEDLINE | ID: mdl-30771347

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Berberine / Colitis, Ulcerative / Proteomics / Molecular Targeted Therapy Limits: Animals Language: En Journal: Eur J Pharmacol Year: 2019 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Berberine / Colitis, Ulcerative / Proteomics / Molecular Targeted Therapy Limits: Animals Language: En Journal: Eur J Pharmacol Year: 2019 Document type: Article Country of publication: